SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — May 23, 2018
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: May 23, 2018 · CIK: 0001659617 · Accession: 0001659617-18-000064
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224243
Letter
Re: Moleculin Biotech, Inc.
Document
May 23, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form S-1
Registration No. 333-224243
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on May 24, 2018, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP 1 filename1.htm Document May 23, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Moleculin Biotech, Inc. Registration Statement on Form S-1 Registration No. 333-224243 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on May 24, 2018, or as soon thereafter as possible on such date. Very truly yours, Moleculin Biotech, Inc. By: /s/ Jonathan Foster Name: Jonathan Foster Title: Chief Financial Officer DC\81934573.1